Home › IPO candidate Atara shifts in deal with Memorial Sloan Kettering
 

Keywords :   


IPO candidate Atara shifts in deal with Memorial Sloan Kettering

2014-09-24 04:26:07| Biotech - Topix.net

Isaac Ciechanover's Atara Biotherapeutics has an option to license three experimental drug programs from Memorial Sloan Kettering Cancer Center. IPO-ready Atara Biotherapeutics could license from Memorial Sloan Kettering Cancer Center three treatments already in human clinical trials for certain cancers and persistent viral infections, the company said Tuesday.

Tags: deal candidate memorial ipo

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Remnants of Fourteen-E Graphics
07.11Remnants of Fourteen-E Forecast Discussion Number 6
07.11Remnants of Fourteen-E Wind Speed Probabilities Number 6
07.11Remnants of Fourteen-E Public Advisory Number 6
07.11Summary for Remnants of Fourteen-E (EP4/EP142024)
07.11Remnants of Fourteen-E Forecast Advisory Number 6
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Advisory Number 17
More »